12:00 AM
 | 
Dec 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MOR208: Phase I started

Xencor began an open-label, dose-escalation, U.S. Phase I trial to evaluate XmAb5574 in 30 patients. In June, Xencor granted MorphoSys exclusive,...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >